Objective: This study aims to evaluate the effects of a new selective estrogen receptor modulator (bazedoxifene acetate [BZA]) and a tissue-specific estrogen complex (BZA combined with conjugated equine estrogens [CEE]) on the extent and severity of cerebral artery atherosclerosis.
P ostmenopausal hormone therapy (HT) is generally considered to be most effective for treating menopausal symptoms and preventing osteoporosis. HT includes estrogen-only therapy (ET) andVfor women with an intact uterusVestrogen + progestogen (EPT). Before the publication of the results from the Women's Health Initiative (WHI) trial, the most commonly prescribed EPT in the United States was the combination of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA). 1 However, the results of studies on both women in WHI 2, 3 and monkeys 4, 5 have provided evidence that the progestin component of EPT increases breast cancer risk; consequently, HT use has declined from approximately 21% in 2000 to approximately 8% in 2009. 6 Studies indicating that progestins may attenuate the potential beneficial effects of estrogens (CEE) on cardiovascular risk have also contributed to recent declines in hormone use. Using the surgically postmenopausal monkey model, Adams et al 7 found that MPA antagonized the inhibitory effects of CEE on coronary artery atherosclerosis. More recently, there have been reports on subgroups of the WHI trial suggesting a reduced risk for coronary heart disease associated with CEE treatment in early postmenopausal women, but not with CEE + MPA. 8<10 In contrast to the data on coronary arteries, we reported that there were no differences between the atherosclerosis-inhibitory effects of CEE alone and the atherosclerosis-inhibitory effects of CEE + MPA on plaque extent in the common and internal carotid arteries. 11 In the WHI trial, not only were there no cerebrovascular beneficial effects of either ET or EPT but a significant increase in ischemic stroke was also observed in both the ET group and the EPT group. 12, 13 Because of the aforementioned concerns about the potentially adverse effects of progestins, alternative HT approaches that protect the endometrium and breast without adversely affecting the progression of atherosclerosis are being sought. Under current investigation is the use of a selective estrogen receptor modulator (SERM) that binds to estrogen receptors > and A with high affinity and acts either as an estrogen agonist or as an antagonist, depending on the target tissue. 14 The new thirdgeneration SERM, bazedoxifene acetate (BZA), has shown considerable promise in the treatment of osteoporosis when given alone and in combination with CEE (often referred to as a tissue-specific estrogen complex [TSEC]); it has become effective for the treatment of menopausal symptoms and the prevention of osteoporosis.
15<17
In anticipation of the possible widespread use of BZA alone for the prevention and treatment of osteoporosis and of the combination of BZA and CEE (TSEC) for the treatment of menopausal symptoms and osteoporosis, we have conducted a randomized, parallel-arm trial with surgically postmenopausal cynomolgus monkeys (Macaca fascicularis) to investigate the effects of these interventions on the breast, uterus, and cardiovascular system. We have reported separately that BZA was an estrogen antagonist capable of abrogating the effects of CEE on the monkey breast 18 and endometrium. 19 We have also reported that BZA had no adverse effects on coronary artery and iliac artery atherosclerosis when given alone but attenuated the atheroprotective effects of CEE when given in combination. 20 In this communication, we report on the effects of these interventions on the extent and severity of cerebral artery atherosclerosis.
METHODS
Details about the animals, the diets they were fed, and the methods used to evaluate plasma lipid and lipoprotein concentrations have been published previously. 19 Briefly, 98 surgically postmenopausal cynomolgus monkeys (M. fascicularis) were given either no treatment (control), CEE alone at a woman's equivalent dose of 0.45 mg/day, BZA at a woman's equivalent dose of 20 mg/day, or a combination of CEE and BZA. Monkeys were fed a diet formulated to model the high-cholesterol (0.29 mg/Cal) and high-fat (35% of calories from fat) diets typically consumed by postmenopausal women in the United States. All hormone treatments were administered in the diet once daily. All procedures involving animals were conducted in compliance with state and federal laws, standards of the US Department of Health and Human Services, and guidelines established by the Wake Forest University Animal Care and Use Committee.
Necropsy procedure
After 20 months of postmenopausal treatment, the monkeys were euthanized using sodium pentobarbital (100 mg/kg, IV), a method consistent with the recommendations of the panel on euthanasia of the American Veterinary Medical Association. The circulatory system was flushed with lactated Ringer's solution, and the left and right common carotid arteries, carotid bifurcations, and internal carotid arteries were dissected free and removed. The cranium was opened, and a block of tissue containing the basilar artery was collected. All arteries were processed for histopathologic evaluation, except for the right common carotid artery, which was frozen for future studies.
Left common carotid artery
The left common carotid artery was opened longitudinally, laid flat on cardboard, and immersion-fixed in 10% neutralbuffered formalin. Three 3-mm-long segments of the proximal, medial, and distal portions of the artery were embedded in three separate paraffin blocks. Five-micrometer sections were made and stained with Verhoeff-van Gieson's stain. Each section was captured digitally using a Nikon DS Fi1 camera mounted on an Olympus BH-2 microscope equipped with a mechanical stage. Morphometric measurements were made using Image-Pro Plus version 5.1 imaging software (Media Cybernetics Inc., Bethesda, MD). Measurements were performed by a single technician (blinded to treatment) with more than 20 years of experience and were reevaluated by T.B.C.
Carotid bifurcations and internal carotid arteries
The left and right carotid artery bifurcations and the internal carotid arteries were immersion-fixed in 10% neutral-buffered formalin. One segment was collected from each artery and embedded in a paraffin block, and 5-Km sections were stained with Verhoeff-van Gieson's stain.
Basilar arteries
The basilar arteries were collected en bloc with a portion of the brain, immersion-fixed in 4% paraformaldehyde for 24 hours, and transferred to 70% ethanol until processing. Two segments of the artery were collected, embedded in two separate paraffin blocks, sectioned, and stained with Verhoeff-van Gieson's stain (as described for previous arteries).
Plaque extent and American Heart Association severity grades
Plaque extent was expressed as the cross-sectional intimal area (IA; mm 2 ). For arteries divided into multiple sections, the mean of IAs (mean IA) was reported as previously described.
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Because plaque complications occur independently of plaque extent, we used a well-established system according to American Heart Association (AHA) guidelines for assigning a severity grade on a scale of 0 to V. Arteries with no lesion were given a score of 0. Intimal lesions with smooth muscle adaptive thickening were given a grade of I. If the smooth muscle adaptive thickening contained macrophage foam cells, a grade of II was given. For those cases in which there had been necrosis of macrophages and accumulation of small pools of extracellular lipid, a grade of III was recorded. A grade of IV was recorded for those lesions in which the small pools of extracellular lipid had coalesced into a core of extracellular lipid. The most complicated plaques observed in this study were given a grade of V, based on the core of the extracellular lipid being separated from the lumen by a definitive fibromuscular cap. AHA grades were determined by a single observer and corroborated by an experienced observer (T.B.C.)
Statistical analysis
The main outcome variables for this study were plaque extent (IA; mm 2 ) and frequency of plaque severity grades (AHA grades 0-V). For arteries in which more than one section of tissue was collected (left common carotid artery, three blocks; basilar artery, two blocks), the extent of artery atherosclerosis was evaluated from each section, and the mean plaque extent (mm 2 ) across sections was calculated. There were no significant differences in plaque extent among sections within each artery (P G 0.05). IA measurements of the left common carotid artery, carotid bifurcations, and internal carotid arteries were square rootYtransformed to improve the normality of the data. One-way analysis of variance was used to compare IA (mm 2 ) between the referent control (CTL) and the three treatment groups. Data were backtransformed and are presented as mean (SEM). Nonparametric analyses (Kruskal-Wallis test) of IAs were also performed using nontransformed data, and the results did not differ from parametric analyses.
Frequency of AHA grades was evaluated using Fisher's exact test, comparing plaque severity for each treatment group with CTL for the distribution of unaffected (0, I) versus affected (QII) lesions. P values were adjusted for multiple comparisons using Bonferroni correction (three comparisons corresponding to each treatment group vs CTL). Statistical significance was set at P G 0.05. Analyses were performed using JMP-9
A (SAS Institute, Cary, NC).
RESULTS

Plasma lipid and lipoprotein concentrations
The mean plasma lipid and lipoprotein concentrations for the control and treatment groups during the experimental period were reported previously 20 and are presented in Table 1 . There were no significant differences among the groups.
Extent and severity of common carotid artery atherosclerosis
The extent (plaque sizes) of atherosclerotic plaques in the common carotid artery for each treatment group is presented in Figure 1 ). Although the overall P value was significant (P = 0.02), none of the treatment groups were significantly different from control. The number of monkeys unaffected by atherosclerosis or with either fatty streaks or complicated plaques (plaque severity) is presented in Table 2 . Unlike the finding for plaque sizes, the monkeys treated with CEE had significantly more unaffected cases (11/24, P = 0.002), whereas the BZA-treated group was indistinguishable from the control group (BZA j1/24 unaffected cases vs CTL j1/23, P = 1.000), and the beneficial effect of CEE treatment on plaque severity seemed to be modestly attenuated by the addition of BZA (CEE + BZA j8/27 vs CTL j1/23 unaffected cases, P = 0.028).
Extent and severity of carotid artery bifurcation atherosclerosis
The extent (plaque sizes) of atherosclerotic plaques in the left and right carotid bifurcations is presented in Figure 2A , B. A significant difference was observed among the groups for both the left artery (overall P = 0.002) and the right artery (overall P = 0.04). The plaque sizes of the CEE-treated monkeys were smaller than those of the control monkeys in the left carotid bifurcation (CTL 0.81T0.12 mm 2 vs CEE 0.46T0.09 mm 2 , ). Overall analysis of variance for any differences among the groups: P = 0.02. P = 0.027). However, after adjustment for multiple comparisons, the results were not significant (left: CEE vs CTL, adjusted P value = 0.08). The plaque sizes in both the left and the right bifurcations of the BZA and BZA + CEE groups were not different from the control group (left: CTL 0.8T0.12 mm 2 vs BZA 1.11T0.14 mm . The distributions of lesion types at the carotid bifurcation are summarized in Table 3 . CEE treatment resulted in more unaffected cases in the right bifurcation (CEE j4/24 vs CTL j0/23 unaffected cases), but the finding did not reach significance.
Extent and severity of internal carotid artery atherosclerosis
The extent (plaque sizes) of atherosclerotic plaques in the left and right internal carotid arteries is presented in Figure 3A , B. A significant difference was observed among the groups for both the left artery (overall P = 0.004) and the right artery (overall P = 0.02). However, CEE treatment had no significant effect on either artery when compared with control (left: CTL 0.19T0.06 mm 2 vs CEE 0.08T0.03 mm Table 4 . CEE-treated monkeys had a significant increase in unaffected cases in the left internal carotid arteries (P = 0.049). CEE had a similar effect on the right internal carotid artery; however, the finding did not reach statistical significance. The distribution of lesion types for the BZA and BZA + CEE groups was not significantly different from the control group.
Severity of basilar artery atherosclerosis
Atherosclerosis occurred so infrequently in the basilar artery that it was not reasonable to calculate a mean plaque extent. The occurrence of basilar lesions among those affected is presented in Table 5 . CEE-treated monkeys had more unaffected cases (19/23, P = 0.050) than the control group. There were no significant differences for the BZA and BZA + CEE groups compared with the control group. Only two monkeys had complicated plaques: one in the control group and one in the BZA group.
DISCUSSION
Stroke is the third leading cause of death in the United States, and its occurrence and pathogenesis are different from those of coronary heart disease, particularly for women. Women are more susceptible to stroke than are men. Among men and women aged 35 to 69 years, the rate of stroke is 2.9% for women compared with 1.07% for men, with the difference being explained by a higher rate in women aged 45 to 54 years. 21 Evidence seems clear that there is a small risk of ischemic stroke (but not hemorrhagic stroke) associated with oral estrogen treatment of postmenopausal women. 12, 13 Ischemic stroke results from primary thrombotic mechanisms and progressing atherosclerosis. The weight of the evidence seems to support that the ischemic strokes of women given oral estrogens are most probably the result of thrombotic mechanisms rather than complications of cerebral artery atherosclerosis. 22 Nevertheless, it is important to consider the potential of exacerbated atherosclerosis when an oral estrogen is combined with a relatively new SERM.
The lack of an effect of BZA and BZA + CEE on the plasma lipid profiles of monkeys contrasts with the reported effects on the plasma lipid profiles of women. BZA resulted in a 3.8% reduction in total plasma cholesterol, a 5.4% reduction in lowdensity lipoprotein cholesterol, and a 5.1% increase in highdensity lipoprotein cholesterol. 23 Lobo et al 15 reported about 10% decreases and 11% increases in low-density lipoprotein cholesterol among women treated with BZA + CEE. However, the beneficial effects of estrogen treatment on the monkey model, and probably among women as well, are thought to be mainly attributable to direct effects on the artery wall and not to changes in plasma lipids and lipoproteins. Therefore, it seems doubtful that the atherosclerosis outcomes of the monkey study would have been different had the monkey's plasma lipid responses been more like those of women because 20 there BZA had no significant effect on plaque extent (size) in the common carotid artery. CEE also had no significant effect on plaque size; however, the prevalence of atherosclerosis was affected beneficially (11/24 unaffected with CEE compared with only 1/23 unaffected in the control group). That beneficial effect was not significantly attenuated by the addition of BZA to CEE treatment (8/27 unaffected with CEE + BZA). The lack of a significant effect of CEE on common carotid artery plaque size may relate to the dose used in this study (a woman's equivalent dose of 0.45 mg/d). In a large previous study of postmenopausal cynomolgus monkeys (56 control monkeys and 62 CEEtreated monkeys), we found about a 50% (P = 0.0001) decrease in plaque size using a CEE dose that was a woman's equivalent dose of 0.625 mg/day. 24 The extent and severity of atherosclerosis at the carotid bifurcation are of high clinical importance because 40% of all clinical events in humans are associated with atherosclerosis at this site. 25 In the study presented here, no evidence indicated exacerbation of atherosclerosis by BZA or by BZA + CEE. . This small effect of CEE on plaque size in the carotid bifurcation is in striking contrast to the atheroprotective effect of CEE against coronary artery atherosclerosis in these same monkeys: about a 40% reduction from control in the carotid bifurcations versus an approximately 70% reduction for coronary artery atherosclerosis. 20 There are two potential explanations for the small CEE effects on the carotid bifurcation. First, cynomolgus monkeys from the same source in Indonesia used in this study may have preexisting plaques at the bifurcation; and, second, glucose intolerance, rather than dyslipoproteinemia, is the primary risk factor for plaque progression in the carotid bifurcations of cynomolgus monkeys. 26 The findings seem clear that BZA or BZA + CEE has no adverse effects on the extent and severity of atherosclerosis in the internal carotid arteries. CEE's lack of significant beneficial effects was unexpected and, again, may relate to the dose of CEE (woman's equivalent dose of 0.45 mg/d) in this study. In two previous studies that used a woman's equivalent dose of 0.625 mg/day, we observed a robust inhibition of internal carotid artery atherosclerosis up to about 70% reduction (P = 0.0003).
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Few nonhuman primate atherosclerosis studies have considered the intracranial arteries, specifically the basilar arteries. In the study reported here, we found some fatty streaks and two monkeys with complicated plaques with no indication of treatment effect. Like atherosclerosis at the carotid bifurcation, atherosclerosis of basilar arteries may be more influenced by abnormalities in carbohydrate metabolism. For example, three of five (60%) female cynomolgus monkeys fed a diet with 1% added cholesterol and 31% fructose developed atherosclerosis in the basilar arteries. 27 Interestingly, the fructose-fed monkeys also had markedly enhanced vasoconstrictor responses in the basilar arteries.
CONCLUSIONS
The results of this study have important clinical implications. It is probable that BZA alone may be used increasingly for the prevention and treatment of osteoporosis and in combination with CEE for the treatment and prevention of postmenopausal symptoms. In the study reported here, no consistent evidence is found to indicate that BZA exacerbated cerebral atherosclerosis. CEE is found to have modest beneficial effects on the severity of cerebral atherosclerosis and, importantly, BZA does not attenuate CEE's inhibition of plaque complications in the common carotid artery. 
